EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study

Dimitrios Basoulis iD, Aikaterini Gkoufa, Elpida Mastrogianni, Angeliki Pantazatou, Ioannis Deliolanis, Anastasia Rigatou, Amalia Karapanou, Sofia Zerva, Maria N Gamaletsou, Michael Samarkos iD, Nikolaos V Sipsas iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf229 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Dimitrios Basoulis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, Laiko General Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Bacteremia, Anti-Bacterial Agents, Enterobacteriaceae Infections, Enterobacteriaceae. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Ceftolozane/tazobactam has been developed as a novel carbapenem-sparing agent. Our study aimed at comparing the effectiveness of ceftolozane/tazobactam versus meropenem for the treatment of bloodstream infections (BSIs) due to ESBL producers.

Methods

This retrospective study was conducted at the Laiko General Hospital of Athens from 1 January 2022 to 28 February 2024. Patients with BSIs due to ESBL-producing Enterobacterales were identified using electronic health records. Inverse probability of treatment weighting (IPTW) was used to compare the two treatment modalities. The primary endpoint was 30 day all-cause mortality; secondary endpoints included clinical cure, in-hospital mortality and antibiotic consumption.

Results

We identified 144 patients with ESBL BSIs, of whom 115 were included in our analysis (ceftolozane/tazobactam, n = 41 versus meropenem, n = 74). The mean age was 73.6 ± 14.1 years and 55.7% (64/115) were male. Persons treated with ceftolozane/tazobactam were older (78.2 ± 13.3 versus 70.9 ± 14 years, P = 0.008) and their isolates were more likely to be susceptible to cefoxitin (2.4% versus 21.6%, P = 0.005). There were no significant differences between the two groups in clinical cure rates (68.3% versus 75.7%, P = 0.511), in-hospital mortality (34.1% versus 29.7%, P = 0.677) or 30 day mortality (34.1% versus 29.7%, P = 0.677). These findings were confirmed by IPTW analysis, which showed no difference between ceftolozane/tazobactam and the carbapenem for clinical cure (OR 0.43, 95% CI 0.12–1.53, P = 0.193), hospital mortality (OR 1.72, 95% CI 0.54–5.51, P = 0.360) and 30 day mortality (OR 1.72, 95% CI 0.54–5.48, P = 0.357).

Conclusions

Ceftolozane/tazobactam is a viable alternative to meropenem for the treatment of ESBL BSIs. Prospective studies are needed to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteremiaAnti-Bacterial AgentsEnterobacteriaceae InfectionsEnterobacteriaceaebeta-Lactamasesbeta-Lactamase InhibitorsMeropenemRetrospective StudiesHumansMaleFemaleMiddle AgedAgedAged, 80 and overHospital MortalityTreatment OutcomeCephalosporinsTazobactam

Substanzen

Anti-Bacterial Agentsbeta-Lactamasesceftolozane, tazobactam drug combinationbeta-Lactamase InhibitorsCephalosporinsTazobactamMeropenem

Autor:innen und Institutionen

  • Department of Pathophysiology, Laiko General Hospital, Athens, Greece.
  • Infectious Diseases Department, Laiko General Hospital, Athens, Greece.
  • Emergency Department, Laiko General Hospital, Athens, Greece.
  • Microbiology Department, Laiko General Hospital, Athens, Greece.
  • Infection Control Department, Laiko General Hospital, Athens, Greece.
  • 1st Internal Medicine Department, Laiko General Hospital, Athens, Greece.

ORCID-Profile: Dimitrios Basoulis, Michael Samarkos, Nikolaos V Sipsas

Zitieren

APA

Basoulis, D., Gkoufa, A., Mastrogianni, E., Pantazatou, A., Deliolanis, I., Rigatou, A., Karapanou, A., Zerva, S., Gamaletsou, M. N., Samarkos, M., & Sipsas, N. V. (2025). Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf229

Vancouver

Basoulis D, Gkoufa A, Mastrogianni E, Pantazatou A, Deliolanis I, Rigatou A, et al. Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf229

BibTeX
@article{Basoulis2025,
  author = {Basoulis, Dimitrios and Gkoufa, Aikaterini and Mastrogianni, Elpida and Pantazatou, Angeliki and Deliolanis, Ioannis and Rigatou, Anastasia and Karapanou, Amalia and Zerva, Sofia and Gamaletsou, Maria N and Samarkos, Michael and Sipsas, Nikolaos V},
  title = {Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf229}
}
Kostenlos starten →